Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania.
But here’s what you should actually be watching.
The Hot Ticker Is a Two-Drug Bet at a Trillion-Dollar Price
Strip away the narrative and Lilly is a concentration trade dressed up as a growth story. Mounjaro and Zepbound drive the entire P&L, with Mounjaro revenue of $8.66 billion (+125%) and Zepbound at $4.16 billion U.S. (+80%) doing the heavy lifting in Q1. Management itself flags “dependence on relatively few products for significant revenue” as a top risk, and realized prices already declined 13% in Q1 2026 as Mounjaro got folded into China’s national reimbursement list.
You are paying 41x trailing earnings and 31x forward for that risk, on a stock that sits at $1,144.68 after a 48.98% one-year rip. Retail is loaded in: Reddit sentiment hit a peak score of 88 on June 7, with a single “Triple Action GLP’s” post pulling 183 upvotes and 82 comments. When the crowd is this loud, the asymmetric trade is no longer there. The token 0.55% dividend won’t save a retirement portfolio when the multiple compresses.
The Redirect: A Restructured Monopoly Paying You to Wait
Pfizer (NYSE:PFE) is the asset-heavy powerhouse the GLP-1 crowd is ignoring, sitting at $25.70, 19x trailing earnings and just 9x forward. Three reasons it belongs on a retirement-focused radar.
1) The patent cliff just got defused. The bear case on Pfizer was always Vyndamax exclusivity. That bear case is dead: the Vyndamax patent settlement extends effective U.S. exclusivity to June 2031, stabilizing the ATTR-CM franchise through mid-decade. Meanwhile Eliquis grew 13%, Padcev 39%, Nurtec 41%, and Abrysvo 37% last quarter. That is a diversified franchise book.
2) The restructuring is real and the insiders are buying. Management is targeting roughly $7.2 billion in net cost savings by the end of 2027, and Q1 delivered revenue of $14.45 billion and adjusted EPS of $0.75 against a $0.72 estimate. CEO Albert Bourla has acquired phantom stock seven times in three months, and on April 23, 2026, eleven directors simultaneously acquired shares at $26.67. Zero insider selling. That is alignment.
3) You get an obesity option for free, plus a 6.6% yield. The dividend yield is 6.61%, paid from real free cash flow at a 6.20% FCF yield. On top of that income, Pfizer bought its way into GLP-1 with the ~$7 billion Metsera acquisition (ten ultra-long-acting obesity assets), in-licensed a PD-1xVEGF bispecific from 3SBio, and launched ecnoglutide in China on April 27, 2026. The Lyme vaccine posted 73.2% efficacy in Phase 3. You are not paying for any of this optionality at 9x forward earnings.
The Action
Bourla put it plainly on the Q1 call: “I’m particularly encouraged by what we’re seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.” The crowd is buying the trillion-dollar GLP-1 story at the top of its hype cycle. Put Pfizer on the watchlist and let the headline chasers tell you how this ends.
Top Gaining Stocks
Top Losing Stocks